PDA

View Full Version : Multiple Sclerosis Research

Pages : 1 [2]
  1. Nguyen, et al. (2003). Sex differences in in vitro pro-inflammatory cytokine production from peripheral blood of multiple sclerosis patients.
  2. Arevalo-Martin, et al. (2003). Therapeutic action of cannabinoids in a murine model of multiple sclerosis.
  3. Jin, et al. (2003). Birth cohort effects in multiple sclerosis.
  4. Hu, et al. (2003). Protein kinase and protein phosphatase expression in amyotrophic lateral sclerosis spinal cord.
  5. Tsunoda, et al. (2003). Axonal injury heralds virus-induced demyelination.
  6. Stefano, et al. (2003). Multiple sclerosis: Stem the tide
  7. Pluchino, et al. (2003). Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis.
  8. Baker & Hankey (2003). Gene therapy in autoimmune, demyelinating disease of the central nervous system.
  9. T'Hart, et al. (2003). Gene therapy in nonhuman primate models of human autoimmune disease.
  10. Bettelli, et al. (2003). Myelin Oligodendrocyte Glycoprotein-specific T Cell Receptor Transgenic Mice Develop Spontaneous Autoimmune Optic Neuritis.
  11. Dalton, et al. (2003). New T2 lesions enable an earlier diagnosis of multiple sclerosis in clinically isolated syndromes.
  12. Takahashi, et al. (2003). Interleukin-1beta promotes oligodendrocyte death through glutamate excitotoxicity.
  13. Dhib-Jalbut, et al. (2003). Glatiramer acetate (Copaxone(R)) therapy for multiple sclerosis.
  14. Karpus, et al. (2003). Immunoneutralization of chemokines for the prevention and treatment of central nervous system autoimmune disease.
  15. FitzGerald, et al. (2003). Transcription factor expression and cellular redox in immature oligodendrocyte cell death: effect of Bcl-2.
  16. Benatru, et al. [Gustatory disorders during multiple sclerosis relapse]
  17. Targeting Multiple Sclerosis as an Autoimmune Disease with Intensive Immunoablative Therapy and Immunological Reconstitution: A Potential Curative Therapy for Patients with Predicted Poor Prognosis MS
  18. Tsunoda, et al. (2003). Axonal injury heralds virus-induced demyelination.
  19. Hoffmann, et al. (2003). Efficacy and safety of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients.
  20. Houzen, et al. (2003). The prevalence and clinical characteristics of MS in northern Japan.
  21. Ozakbas, et al. (2003). Childhood and juvenile onset multiple sclerosis: clinical and paraclinical features.
  22. Gadoth (2003). Multiple sclerosis in children.
  23. Impaired remyelination and depletion of oligodendrocyte progenitors does not occur following repeated episodes of focal demyelination in the rat central nervous system
  24. Liu, et al. (2003). Bilirubin as a potent antioxidant suppresses experimental autoimmune encephalomyelitis: implications for the role of oxidative stress in the development of multiple sclerosis.
  25. Craner, et al. (2003). Co-localization of sodium channel Nav1.6 and the sodium-calcium exchanger...
  26. Oleszak, et al. (2004). Theiler's Virus Infection: a Model for Multiple Sclerosis.
  27. Roelcke, et al. (2004). Functional MRI study of hemiatrophy in MS
  28. Anderson, et al. (2004). MRI imaging of labeled T-cells in a mouse MS model
  29. Karnezis, et al. (2004). Nogo A is involved in autoimmune demyelination.
  30. Fay, et al. (2004). Manual wheelchair pushrim dynamics in people with multiple sclerosis.
  31. Who know "EDWARD GURR Ltd"?
  32. New Drug For Multiple Sclerosis
  33. Low Dose Naltrexone Hypothesis published
  34. Ms
  35. Paintlia, et al. (2005). HMG-CoA reductase inhibitor augments survival and differentiation of oligodendrocyte progenitors in animal model of multiple sclerosis.
  36. Lalive, et al. (2005). TGF-beta-treated microglia induce oligodendrocyte precursor cell chemotaxis through the HGF-c-Met pathway.
  37. Bieber, et al. (2005). Genetically dominant spinal cord repair in a murine model of chronic progressive multiple sclerosis.
  38. Dunning, et al. (2004). Superparamagnetic iron oxide-labeled Schwann cells and olfactory ensheathing cells can be traced in vivo by magnetic resonance imaging and retain functional properties after transplantation into the CNS.
  39. ?
  40. Novartis FTY720 in trial stage III
  41. (MS) Stem cell therapy helps MS woman
  42. Rog, et al. (2005). Randomized, controlled trial of cannabis-based medicine in centra
  43. Herbal Supplement for MS
  44. Act
  45. MS: Dad to sell rally car to pay for daughter’s stem cell procedure
  46. Something New?
  47. UBC study's findings challenge impact of MS on males
  48. Plasma homocysteine levels in multiple sclerosis
  49. Multiple Sclerosis (ms) Patients Improve After Stemcell Use
  50. Warning Letter from FDA
  51. UT Southwest Reperative Cells in MS......
  52. A randomized, placebo-controlled trial of natalizumab for relapsing MS
  53. How Many Americans Have Multiple Sclerosis? No One Knows With Absolute Certainty
  54. MS and glatiramer acetate
  55. Differential cognitive impairment for diverse forms of multiple sclerosis
  56. Continued Administration of CNTF in Experimental Autoimmune Encephalomyelitis
  57. Multiple sclerosis is linked to Epstein-Barr virus infection.
  58. Electroretinographic abnormalities in multiple sclerosis
  59. Combined cannabinoid therapy via an oromucosal spray.
  60. Think you have mild MS that doesn't need treatment?
  61. followup.
  62. Longitudinal follow-up of "benign" multiple ...
  63. Sativex provides relief of spasticity for patients with Multiple Sclerosis
  64. Modified bone marrow cells can help recovery in an animal model of multiple sclerosis
  65. Locomotor training using body weight support on a treadmill improves mobility in pers
  66. Eye scan helps detect multiple sclerosis
  67. MS and FES
  68. Exercise and brain health--implications for multiple sclerosis
  69. The potential use of stem cells in multiple sclerosis
  70. Myelin repair strategies: a cellular view.
  71. Stem cell based delivery of IFN and MS
  72. Schwann cell transplantation for CNS repair.
  73. Notch3 inhibition and MS
  74. Inhibition of rho family functions by lovastatin and MS
  75. Multiple sclerosis and physical exercise
  76. The promise of stem cell and regenerative therapies for multiple sclerosis.
  77. Neuroprotection and immunomodulation with mesenchymal stem cells
  78. Autologous haematopoietic stem-cell transplantation in multiple sclerosis
  79. Serum brain-derived neurotrophic factor response to aerobic exercise in MS
  80. Paving the axonal highway: from stem cells to myelin repair.
  81. From fish to man: understanding endogenous remyelination in CNS diseases.
  82. The biology of CNS remyelination: the key to therapeutic advances.
  83. Cellular remyelinating therapy in multiple sclerosis.
  84. Neuroprotection and immunomodulation with mesenchymal stem cells
  85. Zamboni Paper on Chronic venous Insufficiency & MS
  86. Feasibility investigation of allogeneic endometrial regenerative cells.
  87. Human bone marrow-derived mesenchymal stem cells
  88. Endogenous remyelination is induced by transplant rejection in a viral model of MS
  89. In search of human oligodendroglia for myelin repair.
  90. Regeneration and repair in multiple sclerosis: the role of cell transplantation.
  91. Protective effects of microglia in multiple sclerosis.
  92. Non-expanded adipose stromal vascular fraction cell therapy for multiple sclerosis.
  93. Allogeneic mesenchymal stem cells transplantation in treatment of multiple sclerosis.
  94. BDNF gene delivery in an animal model of MS
  95. Preliminary evidence that self-efficacy predicts physical activity in MS
  96. Potential role of soluble human leukocyte antigen-G molecules in multiple sclerosis.
  97. Directing human neural stem/precursor cells into oligodendrocytes
  98. Preliminary evidence that self-efficacy predicts physical activity in MS
  99. Human neural stem cells ameliorate autoimmune encephalomyelitis in non-human primates